ALNYLAM PHARMACEUTICALS INC (ALNY)       219.64  -6.56 (-2.9%)

Alnylam Anuncia a Aprovação de AMVUTTRA® (vutrisirana sódica) no Brasil para o Tratamento da Amiloidose Hereditária mediada por Transtirretina (hATTR) em Adultos

/PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa líder em terapias de RNAi, acaba de anunciar que a Agência Nacional de Vigilância...

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

Alnylam Halts Work on Eye Drug, Citing New US Law Over Pricing

Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

3 Top Biotech Stocks Defying the Bear Market

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

Alnylam Announces New Management Appointments

Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy